The major focus of Apricity Therapeutics Inc. (Apricity) is the exploitation of influx transporters to enhance the efficacy and reduce the toxicity of drugs. Cancer chemotherapy is the pharmacologic class of drugs that derives the greatest benefit from exploitation of influx transporters. Currently resident in JLab San Francisco, a primary effort of the firm is to target marketed anti-cancer drugs with narrow therapeutic indices to highly expressed influx transporters on cancer cell membranes. With a particular interest on the treatment for pediatric orphan cancers, the company approach allows cancer patients to receive larger doses of chemotherapy with pushes chemotherapy agents directly to tumors. The firm is exploiting transporters in the solute carrier superfamily (SLC) . These transporters are used by tumour cells to accumulate essential nutrients such as sugars, nucleosides and amino acids. Its drug pipeline includes transporter-targeted platinum analog for Pediatric tumour (Phase 1) and for Neuroblastoma (Phase 1). The company is also developing genetic-based diagnostic tests to aid medication selection and dosing.
